Rifinah 150 mg/ 75 mg, 300 mg FC tablets
PDF Leaflet Revision Date: 24 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary and extra-pulmonary tuberculosis.
Dosage (summary)
Daily for 4 months; 10 mg/kg Rifampicin and 5 mg/kg Isoniazid.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; may cause post-natal hemorrhages.
Key Drug Interactions
- Saquinavir/ritonavir
- Halothane
- Oral contraceptives
Contraindications
- Hypersensitivity to rifamycins
- Jaundice
- Acute porphyria
Common side effects
- Nausea
- Vomiting
- Headache
- Dizziness
Counselling Points
- Monitor for liver function
- Avoid alcohol
- Report signs of hypersensitivity
Serious warnings
- Hepatotoxicity
- Severe hypersensitivity reactions
- Risk of bleeding
Important Disclaimer
The Rifinah 150 mg/ 75 mg, 300 mg FC tablets professional information leaflet below is the property of Sanofi-Aventis South Africa (Pty) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
